Anal fissure

Tavanta Therapeutics to Showcase Specialty Pipeline During the 2023 American Society of Clinical Oncology (ASCO) and American Society of Colon and Rectal Surgeons (ASCRS) Annual Congresses

Retrieved on: 
Wednesday, May 31, 2023

"At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.

Key Points: 
  • "At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.
  • Currently, non-surgical options to treat anal fissures include topical nitrates (which are limited by headache/tolerability) and topical calcium channel blockers (which are only available via compounding pharmacies as none are FDA-approved for anal fissure).
  • Based on the data that will be presented, we believe that TAVT-119 has the potential to offer patients a therapeutic option that is safe, efficacious and accessible."
  • "We are pleased to highlight these promising new data, which reflect the significant progress of our clinical development programs," said Lynne Powell, Chief Executive Officer of Tavanta Therapeutics.

GGTOOR, Inc., (OTCMKTS:GTOR) Announces Management Report for the Week Ended August 6, 2022

Retrieved on: 
Tuesday, August 9, 2022

The newest addition to the Yu-Gi-Oh! Duel Links meta -- the anti-synchro deck, Meklords -- dominated this weekend at GGtoor x DLE Yu-Gi-Oh! Duel Links Showdown #32! Many players brought Meklords to counter the synchro-based, Rose Dragon deck that won Showdown #31 two weeks ago. While some of the decks from the previous meta, such as D/D/D, were able to keep up with Rose Dragons in the last Showdown, it seems that they could not deal with both Rose Dragons AND Meklords this time around. These 2 decks absolutely tore up the competition, with the two archetypes EACH representing about 1/3 of the Top 32 cut, and a combined six of the Top eight slots! However, These 2 decks that would reach the finals were neither Rose Dragons nor Meklords; the first was EndS' Galaxy-Eyes, a deck famous for often getting 2nd place in prior metas. The other was Teiko's Phantom Knights, the meta king from the beginning of the year.

Key Points: 
  • Many players brought Meklords to counter the synchro-based, Rose Dragon deck that won Showdown #31 two weeks ago.
  • The other was Teiko's Phantom Knights, the meta king from the beginning of the year.
  • However, EndS' Galaxy-Eyes, with its early-game aggression, out-muscled Phantom Knights Game 2, but not before Teiko revealed EndS' "Shadow-Imprisoning Mirror" tech.
  • Game 3 then progressed similar to Game one, but EndS was prepared for a long-game with his "Shadow-Imprisoning Mirror."

Global Gastrointestinal Drugs Market Report 2022: Focus on Antacids, Antiulcerants, Antiobesity, Antiemetics and Antinauseants, & Antidiarrhoeals - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022

The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.

Key Points: 
  • The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.
  • The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome.
  • The main types of gastrointestinal drugs are antacids, antiulcerants, antiobesity, antiemetics and antinauseants and antidiarrhoeals.
  • During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs.

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Retrieved on: 
Tuesday, January 4, 2022

Claritas is poised to accelerate development of R-107 for treatment of numerous diseases, disorders and injuries, stated Robert Farrell, Claritas President and CEO.

Key Points: 
  • Claritas is poised to accelerate development of R-107 for treatment of numerous diseases, disorders and injuries, stated Robert Farrell, Claritas President and CEO.
  • Our development strategy is straightforward, as follows:
    Phase 1 Study in Q1 2022: The first step is completion of our Phase 1 clinical study to demonstrate that R-107 is safe in humans.
  • Depending on how it is administered, R-107 can target multiple diseases, disorders, and injuries.
  • Claritas Pharmaceuticals, Inc. ("Claritas") is committed to developing new treatments for a variety of diseases and disorders, by discovering, developing, manufacturing, and delivering innovative human therapeutics.

Global Anal Fissure Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Forecasts, Sales & Competitive Landscape 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 12, 2020

The "Global Anal Fissure Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anal Fissure Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Global Anal Fissure Market and Competitive Landscape - 2020, provides comprehensive insights into the Anal Fissure pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Anal Fissure market size and drug sales.
  • Anal Fissure pipeline: Find out drugs in clinical trials for the treatment of Anal Fissure by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Anal Fissure drugs: Identify key drugs marketed and prescribed for Anal Fissure in the US, including trade name, molecule name, and company
    Anal Fissure market valuations: Find out the market size for Anal Fissure drugs in 2019 by countries.

Global Anal Fissure Clinical Trials Review, H2 2018 - Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 27, 2019

The "Anal Fissure Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anal Fissure Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.
  • Global Anal Fissure Clinical Trials Review, H2, 2018" provides an overview of Anal Fissure clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Anal Fissure.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Global Anal Fissure Market and Competitive Landscape Report 2018

Retrieved on: 
Friday, November 2, 2018

The "Global Anal Fissure Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anal Fissure Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • The latest research Global Anal Fissure Market and Competitive Landscape - 2018, provides comprehensive insights into Anal Fissure pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Anal Fissure overview with definitions, symptoms, etiology, diagnosis, treatment options; Anal Fissure pipeline insights covering late stage clinical trials pipeline; Anal Fissure prevalence trends by countries; Anal Fissure market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Anal Fissure pipeline: Find out the drugs in clinical trials for Anal Fissure by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Anal Fissure epidemiology: Find out the prevalence of Anal Fissure by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Anal Fissure products: Identify key products marketed and prescribed for Anal Fissure by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Anal Fissure market size: Find out the market size for Anal Fissure drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Anal Fissure drug sales: Find out the sales of Anal Fissure drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Anal Fissure drugs sales forecast: Sales forecast for Anal Fissure drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Anal Fissure market share analysis: Find out the market shares of Anal Fissure drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?